Mafalda Ramos1, Anastasia Ustyugova2, Nikco Hau3, Mark Lamotte4. 1. IQVIA Global HEOR, Porto Salvo 2740-266, Portugal. 2. Boehringer Ingelheim International GmbH, TA CardioMetabolism Respiratory, Binger Str 173, Ingelheim am Rhein 55216, Germany. 3. Boehringer Ingelheim Ltd, UK Market Access, Bracknell RG128YS, UK (at the time of the study). 4. IQVIA, Global HEOR, Zaventem 1930, Belgium.
Abstract
Aim: Cost-effectiveness (CE) analysis of empagliflozin+standard of care (SoC) compared with SoC and liraglutide+SoC, in patients with Type II diabetes and established cardiovascular disease, was conducted using evidence from cardiovascular outcomes trials. Methods: The IQVIA Core Diabetes Model was calibrated to predict same outcomes observed in EMPA-REG OUTCOME and LEADER trials. Three-year observed cardiovascular events of SoC, empagliflozin+SoC and liraglutide+SoC were derived from EMPA-REG OUTCOME trial and an indirect comparison. Time horizon was 50 years and the UK payer perspective was taken. Results: Empagliflozin+SoC dominated liraglutide+SoC with greater quality-adjusted life years and reduced costs. Base-case incremental CE ratio of 6428 GBP/QALY was observed for empagliflozin+SoC versus SoC. Conclusion: Results suggest that empagliflozin+SoC is cost effective versus SoC and liraglutide+SoC.
Aim: Cost-effectiveness (CE) analysis of empagliflozin+standard of care (SoC) compared with SoC and liraglutide+SoC, in patients with Type II diabetes and established cardiovascular disease, was conducted using evidence from cardiovascular outcomes trials. Methods: The IQVIA Core Diabetes Model was calibrated to predict same outcomes observed in EMPA-REG OUTCOME and LEADER trials. Three-year observed cardiovascular events of SoC, empagliflozin+SoC and liraglutide+SoC were derived from EMPA-REG OUTCOME trial and an indirect comparison. Time horizon was 50 years and the UK payer perspective was taken. Results:Empagliflozin+SoC dominated liraglutide+SoC with greater quality-adjusted life years and reduced costs. Base-case incremental CE ratio of 6428 GBP/QALY was observed for empagliflozin+SoC versus SoC. Conclusion: Results suggest that empagliflozin+SoC is cost effective versus SoC and liraglutide+SoC.
Entities:
Keywords:
cardiovascular outcomes; cost–effectiveness; empagliflozin; liraglutide; type II diabetes mellitus
Authors: Lars Holger Ehlers; Mark Lamotte; Sofia Monteiro; Susanne Sandgaard; Pia Holmgaard; Evan C Frary; Niels Ejskjaer Journal: Diabetes Ther Date: 2021-04-15 Impact factor: 2.945